Yes and no. From the publicly available information I haven't seen anything to explain why Acadia should end up making more money from Trof than Neuren long term. That being the case, if positive Ph 3 Trof results are worth AU$1.4B to Acadia then they should be worth at least AU$1.4B, and more reasonably, AU$4B+. That translated to $13 to $33 a share for Neuren.
Its simple maths and has nothing to do with Neuren's current share price. Neuren's share price could be 10c or $20 and the above calculations would remain the same.
Yes and no. From the publicly available information I haven't...
-
- There are more pages in this discussion • 11,934 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.94 |
Change
-0.200(1.52%) |
Mkt cap ! $1.653B | |||
| Open | High | Low | Value | Volume |
| $13.03 | $13.06 | $12.75 | $7.500M | 581.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2300 | $12.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.96 | 2086 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |